Business Standard

Dr Reddy's Labs advances 4%, hits a record high on healthy Q1 numbers

The company's consolidated revenues rose 15 per cent to Rs 4,418 crore, mainly due to growth in US formulations

Dr Reddy's
Premium

Analysts on an average had expected a profit of Rs 496 crore on revenues of Rs 4,170 crore for the quarter.

SI Reporter Mumbai
Shares of Dr Reddy’s Laboratories hit a record high of Rs 4,224, up 4 per cent on the BSE on Wednesday after the company reported a better-than-expected net profit of Rs 579 crore in April-June quarter (Q1FY21), on the back of strong revenue growth. The pharmaceutical company had posted a profit of Rs 663 crore in the year-ago period. The stock surpassed its previous high of Rs 4189.35, touched on June 10, 2020.

The company’s consolidated revenues rose 15 per cent to Rs 4,418 crore, mainly due to growth in US formulations driven by currency tailwinds and strong traction from

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jul 29 2020 | 2:01 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com